Immuneering Taps Terns CFO Andrew Gengos to Lead Financial Strategy
Event summary
- Andrew Gengos, former CFO of Terns Pharmaceuticals, joins Immuneering as CFO effective July 16, 2026.
- Gengos brings over 25 years of biotech leadership experience, including roles at Athira Pharma and Amgen.
- Immuneering's lead candidate, atebimetinib, is in Phase 3 trials for first-line pancreatic cancer.
- Gengos will oversee financial strategy, capital allocation, and investor relations.
- Terns Pharmaceuticals was acquired by Merck & Co. for $6.7 billion.
The big picture
Immuneering's appointment of Andrew Gengos as CFO underscores its push toward late-stage clinical development and potential commercialization. Gengos' background in high-value biotech acquisitions, including Terns' $6.7 billion deal with Merck, suggests a strategic focus on maximizing shareholder value through both clinical success and potential M&A. The move comes as Immuneering advances its lead candidate, atebimetinib, in a pivotal Phase 3 trial for pancreatic cancer, a high-stakes indication with significant unmet needs.
What we're watching
- Clinical Milestones
- The pace at which atebimetinib advances through Phase 3 trials will determine Immuneering's near-term valuation.
- Financial Strategy
- How Gengos' experience in navigating biotech growth will shape Immuneering's capital allocation and investor relations.
- Market Positioning
- Whether Immuneering can differentiate itself in the competitive oncology space with its Deep Cyclic Inhibitors.
Related topics